3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Renal Cell
35
Carcinoma, Hepatocellular
17
Neoplasm Metastasis
15
Prostatic Neoplasms
13
Neoplasms
9
Neuroendocrine Tumors
7
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
6
Brain Neoplasms
6
Sarcoma, Ewing
5
Sarcoma
5
Osteosarcoma
5
Kidney Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Transitional Cell
5
Recurrence
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
Clear-cell metastatic renal cell carcinoma
4
Urinary Bladder Neoplasms
3
Lung Neoplasms
3
Carcinoid Tumor
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Pheochromocytoma
2
Paraganglioma
2
Neurofibroma, Plexiform
2
Melanoma
2
Interventions
Radiotherapy
6
Doxorubicin
5
Nivolumab
4
pembrolizumab
3
Sunitinib
3
Ifosfamide
3
Gemcitabine
3
Docetaxel
3
pazopanib
2
Radiation Dose Hypofractionation
2
Radiation
2
Methotrexate
2
Ipilimumab
2
Cisplatin
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
sintilimab
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
itacitinib
1
fludarabine
1
eribulin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Histiocytoma, Malignant Fibrous
×
cabozantinib
×
Clear all
NCT05182164
2025-10-07
PEMBROCABOSARC
Institut Bergonié
Phase 2
Recruiting
119 enrolled